<table>
<thead>
<tr>
<th>Alert</th>
<th>S8 – High-risk medication – may cause significant patient harm when used in error.</th>
</tr>
</thead>
</table>
| Indication | Analgesia/sedation:  
1. During assisted ventilation  
2. During procedures and post-surgery  
3. Neonatal abstinence syndrome secondary to opioids  
4. Analgesia and relief of dyspnoea including in context of palliative care |
| Action | Opioid analgesic – stimulates the μ-δ-opioid (Mu-Delta) receptor heteromer in the central nervous system. 
Modulates neurotransmitters. |
| Drug Type | Opioid analgesic. |
| Trade Name | Ordine (Morphine HYDROCHLORIDE). |
| Presentation | 1 mg/mL oral solution of morphine HYDROCHLORIDE. 
Also commercially available as 2 mg/mL, 5 mg/mL and 10 mg/mL oral solution. |
| Dosage/Interval | Neonatal abstinence syndrome secondary to maternal opioid dependency:  
Starting dose: 0.5 mg/kg/day divided into 4–6 equal divided doses.  
- Increase dose by 10–25% titrated to Neonatal Abstinence Syndrome scores (aiming for scores < 8) and clinical condition.  
- Decrease dose by 10–25% every 2–4 days titrated to Neonatal Abstinence Syndrome scores (when scores ≤ 4) and clinical condition. 

Neonatal abstinence syndrome secondary to infant opioid infusion:  
- If weaning from prolonged intravenous morphine (> 4 days), commence oral morphine using the oral:IV ratio of 2:1 (estimated oral morphine bioavailability 48.5% in neonates) [1]. So the daily oral dose is twice the daily intravenous dose of morphine.  
- If weaning from intravenous fentanyl infusion, we recommend converting the total daily fentanyl dose into the equivalent intravenous morphine dose using the conversion ratio fentanyl:morphine of 1:10 (1 microgram of IV fentanyl is equivalent to 10 microgram of IV morphine) [21]. Convert the intravenous morphine dose to oral morphine dose using the ratio 1:2. That is, oral dose is twice the IV dose. |
| Maximum Daily Dose | 1.3 mg/kg/day. |
| Route | Oral or intragastric. |
| Preparation/Dilution | Administer undiluted. However, if required, dilute dose with sterile water to obtain the required volume; ensure adequately mixed, administer immediately and discard any unused portion. |
| Administration | Oral. Preferably with feeds. |
| Monitoring | Analgesia: All patients should have cardiorespiratory monitoring and be carefully observed, particularly if they are breathing spontaneously. Respiratory depression/apnoea can be reversed with naloxone in opioid-naïve patients.  
In infants with NAS secondary to maternal opioid dependency: Observe for signs of respiratory and cardiac depression. Continuous cardiorespiratory monitoring is recommended if oral morphine dose is > 0.8 mg/kg/day or an additional sedative is used. Naloxone is contraindicated in opioid-dependent neonates. Respiratory depression/apnoea should be treated with supportive measures.  
Observe for urinary retention, abdominal distension or delay in passage of stool.  
Monitor Neonatal Abstinence Syndrome scores in opioid-dependent infants.  
Recommendations:  
- Commence treatment for infants with 3 scores averaging ≥ 8 or 2 scores averaging ≥ 12.  
- Increase treatment 10–25% if scores persistently ≥ 8  
- Reduce treatment by 10–25% of the highest dose every 2–4 days if scores ≤ 4. |
| Contraindications | Hypersensitivity to morphine hydrochloride or any component. |
Precautions

Opioid-naïve infants are at risk of cardiorespiratory depression, particularly if they are breathing spontaneously.

Use with caution in patients with hypersensitivity reactions to other opioids.

Hypotension and bradycardia.

Transient hypertonia.

Ileus and delayed gastric emptying time.

Urinary retention.

Tolerance may develop after prolonged use – wean slowly.

Convulsions.

Renal or hepatic impairment – affect metabolism and excretion.

Drug Interactions

Concomitant use with other CNS depressants potentiates effects of opioids, increasing risk of respiratory depression, profound sedation or coma.

Adverse Reactions

See Precautions.

Compatibility

N/A

Incompatibility

N/A

Stability

6 months once bottle opened.

Storage

Protect from light. Cool dry location (temp < 30°C).

Store in Dangerous Drug (DD) safe and record use in DD register. Discard any diluted unused potion.

Special Comments

Prolonged use (> 5–7 days) may be associated with dependence.

Evidence summary

Efficacy:

**Analgesia in opioid-naïve infants:**

Oral analgesia with morphine for acute or chronic pain has not been systematically evaluated in neonates.

Recommended analgesic doses of morphine sulfate for use in neonates are 0.05-0.1 mg/kg intravenously [3]. Estimated oral morphine bioavailability 48.5% in neonates [1]. (LOE IV GOR C) This equates to an estimated intermittent oral dose 0.1–0.2 mg/kg. Duration of analgesia 4–5 hours [4].

Intravenous morphine mean steady-state serum concentration of 15 ng/mL can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 7.5 microgram/kg/hour at birth (term neonates), 12.5 microgram/kg/hour at 1 month, 20 microgram/kg/hour at 3 months [5, 6]. [LOE IV] As oral morphine bioavailability in neonates averaged 48.5% [1], initial estimated daily oral morphine dose is 360 microgram/day (term infants); 600 microgram/day (at 1 month); 960 micrograms/day (at 3 months) in 4–6 equally divided doses.

**Neonatal abstinence syndrome secondary to maternal opioid dependency:**

Guidelines for the Management of Substance Use During Pregnancy Birth and the Postnatal Period [7]: Pharmacological treatment of infants with NAS due to opioids should be initiated when the Finnegan or modified Finnegan score averages 8 or more on 3 consecutive scores or 12 or more on 2 consecutive scores.

Use of opioids for infants with NAS due to opioid withdrawal:

- An opioid (morphine) should be used as initial treatment for infants with NAS due to opioid withdrawal.
- Use of phenobarbitone or clonidine may reduce withdrawal severity in infants treated with an opioid.

A starting dose of morphine 0.5 mg/kg/day in four divided doses (six-hourly) is recommended. Doses should be titrated to NAS scores, that is, to control infant signs of NAS [8].

It is unclear from the evidence what the starting dose of opioid should be. Most trials have commenced morphine 0.2–0.5 mg/kg per day in divided doses. Doses were titrated to NAS scores (i.e. control of infant signs) [9]. [LOE I GOR B]

**Neonatal abstinence syndrome secondary to infant opioid infusion:**
In neonates and infants receiving opioid infusions, high dose (fentanyl > 2.5 mg/kg) and duration of infusion (> 9 days) was predictive of withdrawal requiring treatment (NAS scores ≥ 8) [10, 11]. (LOE III-2) Infants receiving prolonged fentanyl infusions may be at higher risk of withdrawal symptoms than infants receiving prolonged morphine infusions [12]. (LOE III-2) Management of opioid withdrawal includes gradual opioid weaning, environmental and nursing supportive measures and treatment with methadone, clonidine or both [4].

**Pharmacodynamics/Pharmacokinetics:**
Relative potency of morphine compared to fentanyl is 1:100 (i.e. fentanyl 0.1 mg equivalent to morphine 10 mg) in adults[2]. There is one randomised, controlled trial comparing the continuous infusion of fentanyl (10.5 microgram/kg for 1 hour followed by 1.5 microgram/kg/hour) versus morphine (140 microgram/kg for 1 hour followed by 20 microgram/kg/hour) in newborn infants undergoing mechanical ventilation which revealed equivalent analgesic effect with fewer side effects for fentanyl [21]. The relative potency of fentanyl from this study in newborns compared to morphine is estimated to be 13 to 20:1 [22]. There is no study directly comparing the potency of fentanyl to morphine in newborns. (LOE II GOR B)

Estimated oral morphine bioavailability 48.5% in neonates [1]. (LOE IV GOR C) In adults, morphine’s elimination half-life is similar for the intravenous, intramuscular, subcutaneous and oral routes of administration [13]. Effective morphine concentrations in the range of 10–20 ng/mL have been reported [14, 15]. Concentrations above 20 nanogram/mL have been associated with respiratory depression [16].
The mean morphine half-life is age related, reported as around 9 hours in ventilated preterm infants [17, 18], 6 hours in term infants [18, 19] and 2 hours for infants beyond 11 days age [18].

Stability: Ethanol-free morphine 2 mg/mL oral solution diluted to 0.4 mg/mL with sterile water and stored in a light protected container at room temperature retained 107% of its original concentration after 60 days [20].

**References**


<table>
<thead>
<tr>
<th>Original version Date: 29/05/2017</th>
<th>Author: Neonatal Medicines Formulary Consensus Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Version number: 1.1</td>
<td>Current Version Date: 27/06/2019</td>
</tr>
<tr>
<td>Risk Rating: Low</td>
<td>Due for Review: 27/06/2024</td>
</tr>
<tr>
<td>Approval by: As per Local policy</td>
<td>Approval Date:</td>
</tr>
</tbody>
</table>